We’re thrilled to announce we've received funding from @BARDA to advance LBP-EC01, our first-in-class #CRISPR-engineered #bacteriophage therapy, into Part 2 of our Phase 2 ELIMINATE trial for treating #UTIs caused by drug-resistant E. coli. Read more ➡️globenewswire.com/news-relea…

With #AntibioticResistance on the rise, Locus is pioneering a new approach using bacteriophages to combat infections and other diseases like #IBD. Our AI-designed phage therapy selectively targets harmful bacteria. Read more about our efforts in @WIRED. wired.com/story/crispr-enhan…

Largest ever phage therapy trial shows promise for UTI treatment Urinary tract–infecting E. coli are increasingly antibiotic resistant but phage therapy offers a compelling alternative: cen.acs.org/pharmaceuticals/… .

🫁 𝐂𝐑𝐈𝐒𝐏𝐑-𝐞𝐝𝐢𝐭𝐞𝐝 𝐩𝐡𝐚𝐠𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐞𝐥𝐢𝐦𝐢𝐧𝐚𝐭𝐞𝐬 𝐔𝐓𝐈 𝐢𝐧 𝐏𝐡𝐚𝐬𝐞 2 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥 🫁 US-based Locus Biosciences recently reported positive pharmacokinetic and safety data from the first part of the ongoing Phase 2 trial of CRISPR-edited phage therapy candidate LBP-EC01. LBP-EC01 is being developed as a novel treatment for uncomplicated urinary tract infections caused by drug-resistant E. coli. The data from the trial were published in The Lancet Infectious Diseases. Read our summary of the results here: crisprmedicinenews.com/news/… #crisprmedicinenews #crisprmedicine #crispr #phagetherapy #UTI #MDRbacteria #AMR #crisprtrial #clinicalnews #geneediting

Exciting news! Locus has been awarded $4.1M from @CARB_X to support the development of an engineered #bacteriophage therapy targeting infections caused by antimicrobial-resistant (#AMR) and multi-drug-resistant (#MDR) K. pneumoniae.

NCBiotech portfolio company Locus Bio has announced positive results from the first portion of its Phase 2 trial in drug-resistant UTI, affecting an estimated 150 million people worldwide. Congratulations!

Positive results from Part 1 of our Phase 2 ELIMINATE trial evaluating genetically engineered bacteriophage therapy, LBP-EC01, to treat #UTIs were published in @TheLancet Infectious Diseases. Additionally, dosing has begun in Part 2 portion of this study. globenewswire.com/news-relea…

Check out this @TheBioBuzz article on promising new #microbiome-based approaches to medicine including #PhageTherapy. biobuzz.io/microbiome-medici…

Drug-resistant infections claim ~5M lives annually. At Locus, we’re harnessing the power of #bacteriophages to target and destroy specific bacteria. Our CEO discusses our novel approach in this @voxdotcom article. vox.com/future-perfect/35342…

Our CEO, Paul Garofolo, discussed Locus' work to revolutionize treatments for bacterial infections & other diseases like #IBD with engineered bacteriophage therapies that preserve the microbiome. Learn about our advancements in #precisionmedicine. investmentreports.co/intervi…

Excited for #BIO2024? Want to learn about our work to develop #precisionmedicines including bacteriophage-based therapies to combat antibiotic resistance and treat #immunology diseases including inflammatory bowel disease (#IBD)? Let’s connect. auth.inova-application.com/a…

Celebrating 9 Years of Innovation and Impact! Pioneering #precisionmedicine with engineered bacteriophage therapy, combating antibiotic-resistant infections, and #immunology diseases like #IBD. Grateful for support as we continue revolutionizing treatment! #LocusTurns9

We’re excited to attend #DDW2024! As Locus develops #precisionmedicines to treat #immunology diseases including #IBD, we look forward to meeting with researchers, clinicians, and industry leaders to discuss how together we can push the boundaries of medicine.

Excited to join the @ESCMID Global Conference & CARB-X Investor Day! 🌍 As pioneers in bacteriophage-based precision medicine, Locus looks forward to insightful discussions & collaborations driving innovation in combatting antibiotic resistance. #ESCMIDGlobal #CARBX #AMR

Happy #DNADay24! We honor the discovery of DNA's double helix structure and the remarkable advancements it has led to revolutionize medicine. Locus is dedicated to pushing #biotechnology boundaries, creating a new class of bacteriophage biotherapeutics using #PrecisionMedicine.

🎉 Thrilled to announce that the Locus team exceeded our fundraising goal of $20,000 for the @CrohnsColitisFn Triangle Take Steps Walk!🚶‍♂️💙 We proudly walked in solidarity to raise #IBDAwareness. Huge thanks to all supporters!

Locus is excited to be a 2024 Triangle Take Steps event sponsor to raise #IBD awareness and support the @CrohnsColitisFn! As a Company, we're exploring how #bacteriophages and #PrecisionMedicine may help treat GI conditions including IBD. Learn more. takesteps.crohnscolitisfound…

Thrilled to be at the 6th Bacteriophage Therapy Summit by Hanson Wade Group today. Looking forward to dialogue around realizing the promise of #bacteriophage tx to address #AMR & other health issues. Interested in connecting? Email info@locus-bio.com. bacteriophage-summit.com

With phage therapy, researchers sharpen another arrow in the quiver against antibiotic resistance. trib.al/WGUEpR5